Oncolytics Biotech Collaborators Present Positive REOLYSIN Clinical Trial Results at the 14th World Conference on Lung Cancer
Oncolytics Biotech Inc. (NASDAQ: ONCY) today announced that a presentation covering interim preliminary results from a Phase 2 clinical trial using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer with Kras or EGFR-activated tumours was made today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.
The conference is being held in Amsterdam, the Netherlands from July 3rd - 7th 2011.
(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We're Loving
